Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen
NASDAQ,
Patient has taken Atossa’s Endoxifen for 18 months without side effects and without cancer recurrence SEATTLE, July 30, 2020 (GLO…
Patient has taken Atossa’s Endoxifen for 18 months without side effects and without cancer recurrence SEATTLE, July 30, 2020 (GLO…
Pre-menopausal breast cancer patients have very limited treatment options, commented Steve Quay, Ph.D., M.D., Atossas President…
Patient has taken Atossa’s Endoxifen for 18 months without side effects and without cancer recurrence SEATTLE, July 30, 2020 (GLO…
Patient has taken Atossa’s Endoxifen for 18 months without side effects and without cancer recurrence SEATTLE, July 30, 2020 …
(GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover…
Patient has taken Atossa’s Endoxifen for 18 months without side effects and without cancer recurrence SEATTLE, July 30, 2020 (GLO…
(GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover…
(GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover…
Patient has taken Atossa's Endoxifen for 18 months without side effects and without cancer recurrence SEATTLE, July 30, 2020 (GLO…
(GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:), a clinical-stage biopharmaceutical company seeking to discover and…
Patient has taken Atossa’s Endoxifen for 18 months without side effects and without cancer recurrence SEATTLE, July 30, 2020 (GLO…
(GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover…